TVTX · Travere Therapeutics, Inc.
$58.50
-0.38 (-0.65%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$5.60B
Shares
94.26M
Volume · Sep 30
1.56M
Avg daily vol (3M)
1.5M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$58.88
Open$60.35
Day$58.83–60.47
52W close$23.90–67.52
Avg vol 30d1.5M
Short int13.0M · 13.7% float · 10.4d
Short vol84%
Last earningsAug 4, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 4 wks
filed Aug 4, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$591.33M
Trailing 12 months
Net income (TTM)
−$43.46M
Trailing 12 months
Revenue growth YoY
+48.2%
Year over year
Operating margin
-6.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.1%
Year over year · more shares
Price change (1Y)
+149.5%
Trailing year
Short interest
13.7%
Latest settlement · 10.4 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Travere reported strong Q2 2026 with FILSPARI U.S. net product sales up 96% year-over-year to $141.1 million driven by an early FSGS launch and continued IgAN growth, while advancing the pegtibatinase HARMONY Phase 3 (topline 2H 2027), in-licensing civorebrutinib for $112.5M upfront, and closing a convertible note refinancing that added ~$158M net proceeds.
Bullish
- + FILSPARI U.S. net product sales grew 96% year-over-year to $141.1 million in Q2 2026.
- + Pegtibatinase Phase 3 HARMONY Study continues enrollment with topline data expected in 2H 2027.
- + Pipeline expanded via closing of exclusive civorebrutinib licensing deal with Everest Medicines in July 2026.
- + USPTO issued a Notice of Allowance for a U.S. patent application directed to methods of using FILSPARI in IgA nephropathy, expected to provide coverage into October 2037.
Bearish
- − Operating expenses rose materially, with SG&A up to $96.1 million from $62.6 million year-over-year and R&D up to $60.3 million from $49.4 million, reflecting launch costs and Harmony study investment.
- − The $112.5 million upfront payment to Everest Medicines for civorebrutinib was paid in July 2026, reducing cash post-quarter-end.
- − Gross-to-net discounts for FILSPARI are expected to rise in Q3 and Q4 as more FSGS patients initiate therapy with higher CMS utilization, despite full-year guidance maintained at mid-20%.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
−5%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
80%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+87%
trailing
YTD return
+54%
this year
Relative strength
+75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $62 › 200d $45 — 50d above 200d
Institutional flow
Accumulating
+22% holders QoQ · +88 funds added
Insider flow
Distributing
Net -$42.6K over 90 days · 100% sells
Short interest
Rising
13.74% of float · ▲ +7.9% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
321 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
EPS growth
+93%
Y/Y
Free cash flow
$37.1M
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Peak revenue opportunity across FSGS and IgA nephropathy
· peak
at least $3B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
−5%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
80%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $62 › 200d $45 — 50d above 200d
Institutional flow
Accumulating
+22% holders QoQ · +88 funds added
Insider flow
Distributing
Net -$42.6K over 90 days · 100% sells
Short interest
Rising
13.74% of float · ▲ +7.9% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
321 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24
Now $59 · 80%
Range high $68
vs 200-day avg +31%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TVTX
this stock
Travere Therapeutics, Inc.
|
$5.60B | +54.1% | +110.5% | — | 13.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TVTX | -1.6% | -10.4% | +87.3% | -11.2% | +54.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -0.9% | -10.5% | +75.1% | -10.6% | +42.3% |